These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 17962025)

  • 1. Discovery of long-acting N-(cyanomethyl)-N-alkyl-L-prolinamide inhibitors of dipeptidyl peptidase IV.
    Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Hatayama A; Yamamoto S; Kawabata K; Nakai H; Toda M
    Bioorg Med Chem; 2008 Jan; 16(1):190-208. PubMed ID: 17962025
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Chiou MC; Huang CH; Tseng YJ; Yeh TK; Huang CY; Yeh KC; Huang YW; Wu SH; Wang MH; Chen X; Chao YS; Jiaang WT
    Bioorg Med Chem Lett; 2009 Apr; 19(7):1908-12. PubMed ID: 19269819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific and irreversible cyclopeptide inhibitors of dipeptidyl peptidase IV activity of the T-cell activation antigen CD26.
    Nguyen C; Blanco J; Mazaleyrat JP; Krust B; Callebaut C; Jacotot E; Hovanessian AG; Wakselman M
    J Med Chem; 1998 Jun; 41(12):2100-10. PubMed ID: 9622551
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery and preclinical profile of Saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Augeri DJ; Robl JA; Betebenner DA; Magnin DR; Khanna A; Robertson JG; Wang A; Simpkins LM; Taunk P; Huang Q; Han SP; Abboa-Offei B; Cap M; Xin L; Tao L; Tozzo E; Welzel GE; Egan DM; Marcinkeviciene J; Chang SY; Biller SA; Kirby MS; Parker RA; Hamann LG
    J Med Chem; 2005 Jul; 48(15):5025-37. PubMed ID: 16033281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Synthesis and structure-activity relationships of potent 4-fluoro-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Mikami A; Saito-Hori M; Munetomo E; Kitano K; Chonan S; Saito H; Suzuki A; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2008 Apr; 16(7):4093-106. PubMed ID: 18243000
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [(S)-gamma-(Arylamino)prolyl]thiazolidine compounds as a novel series of potent and stable DPP-IV inhibitors.
    Sakashita H; Akahoshi F; Kitajima H; Tsutsumiuchi R; Hayashi Y
    Bioorg Med Chem; 2006 Jun; 14(11):3662-71. PubMed ID: 16460948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis of novel potent dipeptidyl peptidase IV inhibitors with enhanced chemical stability: interplay between the N-terminal amino acid alkyl side chain and the cyclopropyl group of alpha-aminoacyl-l-cis-4,5-methanoprolinenitrile-based inhibitors.
    Magnin DR; Robl JA; Sulsky RB; Augeri DJ; Huang Y; Simpkins LM; Taunk PC; Betebenner DA; Robertson JG; Abboa-Offei BE; Wang A; Cap M; Xin L; Tao L; Sitkoff DF; Malley MF; Gougoutas JZ; Khanna A; Huang Q; Han SP; Parker RA; Hamann LG
    J Med Chem; 2004 May; 47(10):2587-98. PubMed ID: 15115400
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent and selective proline derived dipeptidyl peptidase IV inhibitors.
    Edmondson SD; Mastracchio A; Beconi M; Colwell LF; Habulihaz B; He H; Kumar S; Leiting B; Lyons KA; Mao A; Marsilio F; Patel RA; Wu JK; Zhu L; Thornberry NA; Weber AE; Parmee ER
    Bioorg Med Chem Lett; 2004 Oct; 14(20):5151-5. PubMed ID: 15380217
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel trans-2-aryl-cyclopropylamine analogues as potent and selective dipeptidyl peptidase IV inhibitors.
    Tsai TY; Hsu T; Chen CT; Cheng JH; Yeh TK; Chen X; Huang CY; Chang CN; Yeh KC; Hsieh SH; Chien CH; Chang YW; Huang CH; Huang YW; Huang CL; Wu SH; Wang MH; Lu CT; Chao YS; Jiaang WT
    Bioorg Med Chem; 2009 Mar; 17(6):2388-99. PubMed ID: 19261480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and structure-activity relationships of potent 3- or 4-substituted-2-cyanopyrrolidine dipeptidyl peptidase IV inhibitors.
    Fukushima H; Hiratate A; Takahashi M; Saito M; Munetomo E; Kitano K; Saito H; Takaoka Y; Yamamoto K
    Bioorg Med Chem; 2004 Dec; 12(23):6053-61. PubMed ID: 15519151
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Design and synthesis of DPP-IV inhibitors lacking the electrophilic nitrile group.
    Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Hatayama A; Yamamoto S; Kishikawa K; Nakai H; Toda M
    Bioorg Med Chem; 2008 Feb; 16(4):1613-31. PubMed ID: 18039579
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel N-substituted 4-hydrazino piperidine derivative as a dipeptidyl peptidase IV inhibitor.
    Gupta RC; Chhipa L; Mandhare AB; Zambad SP; Chauthaiwale V; Nadkarni SS; Dutt C
    Bioorg Med Chem Lett; 2009 Sep; 19(17):5021-5. PubMed ID: 19643608
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [(S)-gamma-(4-Aryl-1-piperazinyl)-l-prolyl]thiazolidines as a novel series of highly potent and long-lasting DPP-IV inhibitors.
    Yoshida T; Sakashita H; Akahoshi F; Hayashi Y
    Bioorg Med Chem Lett; 2007 May; 17(9):2618-21. PubMed ID: 17317162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of potent and selective dipeptidyl peptidase IV inhibitors derived from beta-aminoamides bearing subsituted triazolopiperazines.
    Kim D; Kowalchick JE; Brockunier LL; Parmee ER; Eiermann GJ; Fisher MH; He H; Leiting B; Lyons K; Scapin G; Patel SB; Petrov A; Pryor KD; Roy RS; Wu JK; Zhang X; Wyvratt MJ; Zhang BB; Zhu L; Thornberry NA; Weber AE
    J Med Chem; 2008 Feb; 51(3):589-602. PubMed ID: 18201067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and evaluation of structurally constrained imidazolidin derivatives as potent dipeptidyl peptidase IV inhibitors.
    Wang L; Zhang B; Ji J; Li B; Yan J; Zhang W; Wu Y; Wang X
    Eur J Med Chem; 2009 Aug; 44(8):3318-22. PubMed ID: 19375196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Crystal structures of DPP-IV (CD26) from rat kidney exhibit flexible accommodation of peptidase-selective inhibitors.
    Longenecker KL; Stewart KD; Madar DJ; Jakob CG; Fry EH; Wilk S; Lin CW; Ballaron SJ; Stashko MA; Lubben TH; Yong H; Pireh D; Pei Z; Basha F; Wiedeman PE; von Geldern TW; Trevillyan JM; Stoll VS
    Biochemistry; 2006 Jun; 45(24):7474-82. PubMed ID: 16768443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design and synthesis of new potent dipeptidyl peptidase IV inhibitors with enhanced ex vivo duration.
    Kondo T; Nekado T; Sugimoto I; Ochi K; Takai S; Kinoshita A; Tajima Y; Yamamoto S; Kawabata K; Nakai H; Toda M
    Bioorg Med Chem; 2007 Apr; 15(7):2631-50. PubMed ID: 17293118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of potent, selective, and orally bioavailable oxadiazole-based dipeptidyl peptidase IV inhibitors.
    Xu J; Wei L; Mathvink RJ; Edmondson SD; Eiermann GJ; He H; Leone JF; Leiting B; Lyons KA; Marsilio F; Patel RA; Patel SB; Petrov A; Scapin G; Wu JK; Thornberry NA; Weber AE
    Bioorg Med Chem Lett; 2006 Oct; 16(20):5373-7. PubMed ID: 16919457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (3R)-3-amino-4-(2,4,5-trifluorophenyl)-N-{4-[6-(2-methoxyethoxy)benzothiazol-2-yl]tetrahydropyran-4-yl}butanamide as a potent dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
    Nitta A; Fujii H; Sakami S; Nishimura Y; Ohyama T; Satoh M; Nakaki J; Satoh S; Inada C; Kozono H; Kumagai H; Shimamura M; Fukazawa T; Kawai H
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5435-8. PubMed ID: 18819797
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potent non-nitrile dipeptidic dipeptidyl peptidase IV inhibitors.
    Simpkins LM; Bolton S; Pi Z; Sutton JC; Kwon C; Zhao G; Magnin DR; Augeri DJ; Gungor T; Rotella DP; Sun Z; Liu Y; Slusarchyk WS; Marcinkeviciene J; Robertson JG; Wang A; Robl JA; Atwal KS; Zahler RL; Parker RA; Kirby MS; Hamann LG
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6476-80. PubMed ID: 17937986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.